Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single-centre, Randomized, Double-blind (Sponsor-unblinded), Placebo-controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK2982772 in Repeat Oral Doses in Healthy Subjects

Next Previous
X
Search
Trial Profile

A Single-centre, Randomized, Double-blind (Sponsor-unblinded), Placebo-controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK2982772 in Repeat Oral Doses in Healthy Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 03 Jul 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GSK 2982772 (Primary)
  • Indications Autoimmune disorders; Inflammatory bowel diseases; Plaque psoriasis; Rheumatoid arthritis; Ulcerative colitis
  • Focus Adverse reactions
  • Sponsors GlaxoSmithKline; GSK

    • Most Recent Events

    • 09 Nov 2020 Results of pooled analysis of data pooled from two (NCT03305419 and NCT03590613 ) studies comparing the pharmacokinetics of RIPK1 Inhibitor GSK2982772 in healthy Western and Japanese subjects published in the European Journal of Drug Metabolism and Pharmacokinetics
    • 11 Jan 2019 Status changed from recruiting to completed.
    • 02 Aug 2018 Status changed from suspended to recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top